{"protocolSection":{"identificationModule":{"nctId":"NCT02784717","orgStudyIdInfo":{"id":"16819"},"secondaryIdInfos":[{"id":"XA1207CN","type":"OTHER","domain":"Company internal"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study","officialTitle":"Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study","acronym":"XASSURE"},"statusModule":{"statusVerifiedDate":"2020-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-05-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-02-21","type":"ACTUAL"},"completionDateStruct":{"date":"2019-09-24","type":"ACTUAL"},"studyFirstSubmitDate":"2016-04-27","studyFirstSubmitQcDate":"2016-05-26","studyFirstPostDateStruct":{"date":"2016-05-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-09-02","lastUpdatePostDateStruct":{"date":"2020-09-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Scientific Affairs, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This non-interventional field study will investigate rivaroxaban under clinical practice conditions for stroke prevention and for prevention of non-CNS systemic embolism in patients with non-valvular atrial fibrillation in China.","detailedDescription":"3000 patients will be provided with free drug.It is planned to have an interim analysis(IA) when 3000 patients are enrolled (cut off day is the 3000th patient completed at least 3 months follow-up visit). To end or continue enrolling patients will be decided based on the IA result and the evaluation comments from CFDA."},"conditionsModule":{"conditions":["Stroke"],"keywords":["rivaroxaban,","non-interventional,","atrial fibrillation,","stroke prevention,"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":3055,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban (Xarelto, BAY 59-7939)","description":"Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban to prevent stroke or non-CNS systemic embolism has been made.","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY 59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY 59-7939)","description":"Decision regarding dose and duration of treatment made at the discretion of the attending investigator.","armGroupLabels":["Rivaroxaban (Xarelto, BAY 59-7939)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Major bleeding events","description":"Major bleeding events, collected as serious or non serious adverse events and defined as overt bleeding associated with:\n\n1. a fall in haemoglobin of ≥2 g/dL, or\n2. a transfusion of ≥2 units of packed red blood cells or whole blood, or\n3. occurrence at a critical site (intracranial, intra-spinal, intraocular, pericardial, intra articular, intra-muscular with compartment syndrome, retroperitoneal), or\n4. death","timeFrame":"Up to 30 months"}],"secondaryOutcomes":[{"measure":"Number of Symptomatic thromboembolic events","description":"Collected as serious or non-serious adverse events","timeFrame":"Up to 30 months"},{"measure":"Number of Non-major bleeding","description":"Collected as serious or non-serious adverse events and defined as all bleeding events that do not fall in the category of major bleedings","timeFrame":"Up to 30 months"},{"measure":"Treatment satisfaction questionnaire","timeFrame":"Up to 30 months"},{"measure":"Adverse event and serious adverse event percentage in the different atrial fibrillation risk factor categories","timeFrame":"Up to 30 months"},{"measure":"Number of each reason for any switch from or interruption of rivaroxaban treatment","description":"If the patients switch from or interruption of rivaroxaban treatment, patients or physicians will be asked by several questions about the reasons of the switch and interruption, and collected in CRF. The reasons will be described by frequency distributions.\n\nReason choice as below:\n\n1. Patient choice 2. Insufficient therapeutic effect 3. Adverse event 4. Surgery 5. Dentistry 6. Renal function change","timeFrame":"Up to 30 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male patients ≥ 18 years of age diagnosed with non-valvular atrial fibrillation\n* Patients for whom the decision to initiate treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism was made as per investigator's routine treatment practice\n\nExclusion Criteria:\n\n* NA","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban within approved indication to prevent stroke or non-CNS systemic embolism has been made.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"HangZhou","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Click here to find results for studies related to Bayer products","url":"http://clinicaltrials.bayer.com/"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000004617","term":"Embolism"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}